Supernus Pharmaceuticals (SUPN) has risen sharply, recording gains of 3.85% in the past 4 weeks. However, the stock has corrected -1.86% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 2.79% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 2.81% and the 50-Day Moving Average is 9.87%. Supernus Pharmaceuticals (NASDAQ:SUPN): On Fridays trading session , Opening price of the stock was $23.28 with an intraday high of $23.31. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $22.58. However, the stock managed to close at $22.68, a loss of 2.87% for the day. On the previous day, the stock had closed at $23.35. The total traded volume of the day was 547,815 shares.
The company Insiders own 6.1% of Supernus Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -37.68% . Institutional Investors own 93.59% of Supernus Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -35.19%. Also, Equity analysts at the Brokerage firm Jefferies maintains its rating on Supernus Pharmaceuticals (NASDAQ:SUPN). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Jefferies raises the price target from $23 per share to $28 per share. The rating by the firm was issued on August 4, 2016.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.